Profile: Boston Scientific Corp (BSX)
30 Sep 2016
Boston Scientific Corporation, incorporated on June 22, 1979, is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. The Company operates through three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and PI businesses. Its Rhythm Management segment consists of CRM and EP businesses. Its MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses.
The Company's product offerings under interventional cardiology include Drug-Eluting Coronary Stent Systems, Core Coronary Technology, Intravascular Imaging and Structural Heart Therapy. The Company markets a portfolio of internally-developed and self-manufactured drug-eluting stents, including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. It markets the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating. The Company markets a line of products used to treat patients with atherosclerosis. Its product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, crossing and re-entry devices for the treatment of chronically occluded coronary vessels and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures. The Company markets a range of intravascular catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels. Its Intravascular Ultrasound Imaging catheter, OptiCross, is available in all the markets around the world. The iLab Ultrasound Imaging System is the Company's flagship console and is compatible with its line of imaging catheters, and its Polaris software, designed to run on the iLab System, has been approved in Japan, the United States and Europe. The iLab System is designed to diagnosis and treat blocked vessels and heart disorders. The Company has developed a repositionable and retrievable device for transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis. The Company's subsidiary, Atritech, Inc., has developed a device designed to close the left atrial appendage in patients with atrial fibrillation (AF) who are at risk for ischemic stroke.
The Company has various products designed to treat patients with peripheral disease (disease which appears in blood vessels other than in the heart and in the biliary tree), including a line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. Its peripheral angioplasty balloon technology includes its Mustang PTA balloon; Coyote balloon catheter, a low profile balloon dilatation catheter designed for a range of peripheral angioplasty procedures, and Charger PTA Balloon Catheter, an approximately 0.035 inches percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation, as well as conventional balloon angioplasty to open blocked peripheral arteries. Its peripheral stent technology includes EPIC self-expanding nitinol stent system, Carotid WALLSTENT stent system and Innova self-expanding stent system. In addition, the Company also markets approximately 0.035 inches Rubicon Support Catheter and its Direxion torqueable microcatheter in both the United Statesand Europe. The catheter-based renal denervation system for the treatment of uncontrolled hypertension is available in Europe. In addition, the Company is conducting a study designed to evaluate the safety and performance of the self-expanding Innova drug-eluting stent system designed to treat Superficial Femoral Artery (SFA) lesions. The Company also sells products designed to treat patients with non-vascular disease (disease that appears outside the blood system). Its non-vascular suite of products includes biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company markets its line of Interventional Oncology product solutions, including Renegade HI-FLO Fathom microcatheter and guidewire system, and Interlock-35 Fibered IDC Occlusion System for peripheral embolization.
Cardiac Rhythm Management
The Company develops, manufactures and markets a range of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including Implantable cardioverter defibrillator (ICD) systems used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including the subcutaneous implantable cardiac defibrillator-the S-ICD System, and implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure, and Implantable pacemaker systems used to manage slow or irregular heart rhythms (bradycardia), including implantable cardiac resynchronization therapy pacemaker (CRT-P) systems used to treat heart failure. In addition, many of the Company's implantable device systems include remote LATITUDE Patient Management System, which enables physicians to monitor device performance remotely, allowing for more frequent monitoring in order to guide treatment decisions. The Company also markets INGENIO family of pacemaker systems in the United States, Europe and Japan. Its INGENIO and ADVANTIO pacemakers are approved in Europe and Japan for use in patients in need of a magnetic resonance imaging (MRI) scan. Its cardiac resynchronization therapy pacemaker product offerings include INVIVE system, which is enabled for remote patient monitoring. The Company received CE Mark approval and performed the first implants of its X4 line of quadripolar CRT-D systems, including AUTOGEN X4, DYNAGEN X4, and INOGEN X4 cardiac resynchronization therapy defibrillators, a suite of ACUITY X4 quadripolar LV leads and the ACUITY PRO lead delivery system. It also received CE Mark for a new MINI line and a new extended longevity (EL) line of ICDs. DYNAGEN X4, INOGEN X4, DYNAGEN MINI and INOGEN MINI are also approved by the United States Food and Drug Administration (FDA).
The EP business of the company is engaged in the development of less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Its product offerings are steerable radio frequency (RF) ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths and other accessories. Its products include the Blazer line of temperature ablation catheters designed to deliver performance and responsiveness. Its cooled ablation portfolio includes a closed-loop irrigated catheter, the Chilli II cooled ablation catheter, and CE Mark approved Blazer Open-Irrigated ablation catheter with a Total Tip Cooling Design. Its diagnostic catheter portfolio includes Blazer Dx-20, Dynamic Tip and Viking catheters. The Company received a FDA approval for the IntellaTip MiFi XP catheter, with MicroFidelity sensor technology, an ablation catheter used for the treatment of atrial flutter. The Company's capital equipment product offerings include LabSystem Pro Recording System, the Rhythmia Mapping System, Maestro radio frequency (RF) generators and the MetriQ pump (CE Mark approved).
The Company offers products for the diagnosis and treatment of a range of pulmonary and gastrointestinal conditions with less invasive technologies. Common disease states include esophageal disorders, gastrointestinal (GI) strictures and bleeding, biliary disease and conditions, as well as esophageal, biliary, pancreatic and colon cancer. Its product offerings include Spyglass System, which is a single-operator cholangioscopy system that offers clinicians direct visualization of the pancreatico-biliary system and includes therapeutic devices for managing biliary stones and strictures; WallFlex Colonic Stents, which have been shown to reduce patient postoperative length of stay; Resolution Clip, a technology used to provide hemostasis and closure within the GI System; Expect Aspiration Needle, which is a flexible and highly visible needle used with endoscopic ultrasound enabling physicians to target and sample lesions in the GI system with a high degree of accuracy, and RX Biliary System devices that are designed to provide greater access and control for physicians to diagnose and treat challenging conditions of the bile ducts, such as removing gallstones, opening obstructed bile ducts and obtaining biopsies in suspected tumors. Its WallFlex Biliary RX Stents provide relief for pancreatic cancer patients receiving chemotherapy before undergoing surgery through pre-operative drainage of the bile duct and its WallFlex Esophageal Stents deliver luminal patency in patients with esophageal strictures.
The Company also markets devices to diagnose, treat and ease pulmonary disease systems within the airway and lungs. Its products are designed to help perform biopsies, retrieve foreign bodies from the airway, open narrowings of an airway, stop internal bleeding, and ease symptoms of some types of airway cancers. Its product line includes pulmonary biopsy forceps, transbronchial aspiration needles, cytology brushes and tracheobronchial stents used to dilate narrowed airway passages or for tumor management. The Endoscopy portfolio also offers a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma called the Alair Bronchial Thermoplasty System. The Alair Bronchial Thermoplasty System is a device-based asthma treatment.
Urology and Pelvic Health
The Company's Urology and Pelvic Health business develops, manufactures and sells devices to treat various urological and pelvic disorders. Within its Urology business, the Company sells a range of products designed to treat patients with urinary stone disease and benign prostatic hyperplasia (BPH). It offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons and catheters. Within its Pelvic Health business, the Company markets a range of devices for the treatment of conditions, such as stress urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), menorrhagia (excessive menstrual bleeding), uterine fibroids and polyps, and erectile dysfunction. It offers a full breadth of mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits and suturing devices. It markets Genesys Hydro ThermAblator (HTA) system, an ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. In the United States, the Company is developing the Symphion System for the removal of intrauterine fibroids and polyps.
In the Neuromodulation business, the Company markets the Precision and Precision Spectra Spinal Cord Stimulator (SCS) systems used for the management of chronic pain. These systems manage chronic pain by applying an electrical signal to mask pain signals traveling from the spinal cord to the brain. Its lead portfolio includes the CoverEdge family of 32-contact surgical leads, the Infinion 16 Percutaneous Lead, and Linear 3-4 and Linear 3-6 Percutaneous Leads. The Precision Spectra SCS System is a SCS system with over 30 contacts and approximately 30 power sources and is designed to provide improved pain relief to a range of patients who suffer from chronic pain. The Company is conducting over two clinical trials exploring stimulation with multiple new waveforms based on the Precision and Precision Spectra platforms: ACCELERATE study evaluating high-rate stimulation and the WHISPER study exploring a sub-perception stimulation waveform.
The Company competes with Abbott Laboratories, Medtronic plc, St. Jude Medical, Inc. and Cook Medical.
Boston Scientific Corp
300 BOSTON SCIENTIFIC WAY
MARLBOROUGH MA 01752-1234
Company Web Links
- BRIEF-EndoChoice holdings agreement with Boston Scientific provides termination fee of $7.95 million under certain circumstances
- BRIEF-Boston Scientific to acquire EndoChoice for $8.00/share
- BRIEF-Paulson & Co raises share stake in Valeant, Facebook - SEC filing
- BRIEF-Boston Scientific gets FDA approval for Emblem MRI system
- Boston Scientific's sales beat on demand for heart devices